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Immunotherapy has a great potential in advancing cancer treatment, especially in light 
of recent discoveries and therapeutic interventions that lead to complete response in 
specific subgroups of melanoma patients. By using the body’s own immune system, it 
is possible not only to specifically target and eliminate cancer cells while leaving healthy 
cells unharmed but also to elicit long-term protective response. Despite the promise, 
current immunotherapy is limited and fails in addressing all tumor types. This is prob-
ably due to the fact that a single treatment strategy is not sufficient in overcoming the 
complex antitumor immunity. The use of nanoparticle-based system for immunotherapy 
is a promising strategy that can simultaneously target multiple pathways with the same 
kinetics to enhance antitumor response. Here, we will highlight the recent advances 
in the field of cancer immunotherapy that utilize lipid-based nanoparticles as delivery 
vehicles and address the ongoing challenges and potential opportunities.
Keywords: lipid nanoparticles, cancer immunotherapy, sirNA therapeutic, tumor microenvironment, cancer 
vaccines
iNtrODUctiON
tumor immunology
Hundred years after Paul Ehrlich coined the term “magic bullet,” it is well established that the 
immune system can be utilized in the epic battle against cancer. Immune cells possess a unique ability 
to distinguish between cancer and normal cells with reliance on specific expression of cell-surface 
tumor-associated antigens (TAA) or self-antigens. Due to this ability, immune cells can act as “killing 
bullets” that are able to specifically eliminate tumors cells.
The development of a tumor is a dynamic process whereby the immune system not only protects 
against cancer development but also shapes the character of emerging tumors, a process named 
“Cancer Immunoediting.” This complex process can be divided to three phases according to the 
nature of the interaction of tumor cells with the immune system: elimination, equilibrium, and 
escape (1).
In the elimination phase, both the innate and adaptive immune systems detect and destroy 
early tumors (2). Tumor cells express TAA-derived peptides in context of MHC molecules that 
are recognized by TAA-specific-cytotoxic CD8+T-lymphocytes (CTL). Activated CTL and natural 
killer (NK) cells directly induce tumor cell apoptosis and, in addition, release IFN-γ that medi-
ates inhibition of tumor-cell proliferation and angiogenesis. Antigen-presenting cells (APCs), 
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such as tumor-associated macrophages (TAMs) and dendritic 
cells (DC), take up TAAs from tumor cells debris and present 
their peptides in the context of MHC to TAA-specific CD8+ and 
CD4+T-lymphocytes. Activated CD4+T-lymphocytes produce 
inflammatory cytokines such as, IFN-γ and TNF-α, that can 
both suppress tumor survival and upregulate the expression of 
MHC molecules on the surface of tumor cells. This upregulation 
facilitates the recognition of cancer cells by CTL, which mediates 
their killing mechanism (1, 3).
The equilibrium phase is a balance phase upon which 
tumor progression is still controlled by the immune system; 
however, sporadic tumor cells manage to survive immune 
destruction (1, 4).
In the escape phase, tumors manage to evade immune 
surveillance, begin to grow progressively and establish an 
immunosuppressive tumor microenvironment (TME) (1, 5, 6). 
In this phase, tumor cells acquire the ability to escape from host 
immune response through different strategies; first, tumor cells 
downregulate MHC expression, thus preventing recognition and 
attack by CTL (7). Second, tumor cells upregulate their expres-
sion of immune checkpoints proteins, such as PD-L1 and CD80/
CD86, which ligate the negative co-stimulators PD1 and CTLA4 
on the T-lymphocyte’s membrane. This results in attenuation of 
T-lymphocytes activation (8, 9). Furthermore, tumor cells induce 
the infiltration of other cell types (fibroblasts, endothelial, and 
immune cells) and instruct them to establish TME that promotes 
tumor progression (10). For example, infiltration of regulatory 
T-cells (Tregs) into the TME inhibits CTL (11). Finally, tumor cells 
encourage cells in TME to release anti-inflammatory cytokines, 
such as IL-10 and TGF-β. These cytokines suppress the ability 
of resident immune cells to act against tumor cells, prevent the 
recruitment of CTL and NK cells, and, therefore, promote tumor 
growth (12).
In the past few years, the rapidly advancing field of cancer 
immunotherapy has produced several new opportunities for 
treating cancer: either by stimulating the activities of specific 
components of the immune system or by counteracting immu-
nosuppressive signals produced by tumor cells. Efficient anti-
tumor immunotherapy can be achieved by combining delivery 
of TAAs to APC along with removing tumor-derived negative 
regulators of immune cell activation (13, 14). Therefore, delivery 
of immunomodulatory molecules to the appropriate cells is 
crucial for the successful development of cell-based antitumor 
immunotherapy.
Nanotechnology-Based therapies
Nanotechnology affords a unique opportunity to deliver 
therapeutic molecules to specific cells and simultaneously 
attack several biological avenues promoting tumor eradica-
tion (15). A variety of delivery platform vehicles are under 
development to target immune cells, such as antibodies (16), 
polymers (17), aptamers (18), and lipid nanoparticles (LNPs) 
(19, 20). In comparison to other NPs, LNPs have attractive 
biological properties, which include general biocompatibility, 
biodegradability, and the ability to entrap both hydrophilic and 
hydrophobic drugs (15, 21). Multiple properties of LNPs can be 
altered via different lipid composition and ratios or by surface 
chemistry, including their size, charge, and surface functional-
ity (22). LNPs serve as carriers for a variety of therapeutic 
molecules: from nucleic acid to proteins, small molecules and 
chemotherapy drugs, and combinations of the aforementioned 
agents (22–24). LNPs shelter their cargo from clearance in 
the surrounding biological milieu, increasing the half-life in 
circulation, minimizing systemic toxicity, and hence enabling 
a wide therapeutic window (15, 22, 25). In addition, LNPs can 
promote delivery of their cargo directly to specific immune 
cell, such as APC or T-lymphocytes (20, 26, 27). Here, we 
review the latest developments in nanoparticle-based cancer 
immunotherapy, centering on LNPs.
tHe eFFects OF tHe 
PHYsicOcHeMicAL PrOPerties 
OF LNPs ON iMMUNe MODULAtiON
The physicochemical characteristics of LNPs are crucial for 
their fate and performance following administration. Several 
parameters were examined including nanoparticle size, shape, 
surface charge, lipid composition, and aggregation. Size is one 
of the major causes for immune stimulation by LNPs. This can 
be related to the fact that these nanoparticles fall within the 
size range of pathogens, such as viruses and small bacteria (28). 
Size has a significant impact on blood circulation half-life as 
an optimal vesicle should be large enough to avoid renal clear-
ance but small enough to avoid clearance via the mononuclear 
phagocytic system (15). The size of NPs should be also adjusted 
in accordance to the route of administration and delivery pur-
poses. For example, it was shown that, following intravenous 
administration, 25 nm size NPs are significantly more efficient 
than 100  nm-sized NPs, as these smaller nanoparticles are 
better delivered to the lymph nodes (29). In addition, size of 
below 100 nm enables NPs to utilize the enhanced permeabil-
ity and retention effect characteristic of solid tumors. Below 
100 nm, NPs can reach solid tumors by extravasation via the 
leaky tumor vasculature and accumulate due to poor lymphatic 
drainage (15).
The shape and curvature of NPs can also affect immune 
activation as it was shown that oblate-shaped NPs have 
a lower macrophage uptake in comparison to spherical 
nanoparticles and, therefore, longer circulation time and altered 
biodistribution (30).
Surface features of LNPs have also been thoroughly investi-
gated. Surface charge is another major contributor of immune 
activation, as positively charged LNPs can better interact with 
the negatively charged mucosal surface. This results in better 
uptake of positively charged LNPs by cells in comparison to 
their negatively charged or neutral counterparts (31). However, 
positively charged LNPs have toxic effects including induc-
tion of pro-inflammatory response (32). Surface charge (both 
negative and positive) and high membrane cholesterol content 
are also related to complement activation by liposomes (28). 
Contrarily, the presence of phosphatidylserine (PS) has an anti-
inflammatory effect probably due to specific recognition by PS 
receptors (33, 34).
FigUre 1 | Antitumor vaccine. Lipid nanoparticles (LNPs) can be loaded with tumor antigens and adjuvants for the purpose of targeting antigen-presenting cells, 
such as dendritic cells (DCs). Following uptake, the LNPs degrade and release the antigen and adjuvant, which stimulates DC maturation and antigen presenting on 
cell-surface MHC molecules. This context enables recognition and binding of CD8+ T-lymphocytes and results in their activation, proliferation, and antitumor response.
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Surface functionalization has been widely used to improve 
LNPs performance. One of the main causes for the immune rec-
ognition of LNPs is the absence of self-discriminating molecules 
(such as complement control proteins) on the bilayer mem-
brane, which protect “self ” cells from attack by the complement 
system (28). Among the most common of these are hydrophilic 
moieties, such as polyethylene glycol (PEG), which enables 
prolonged blood circulation time and improved biodistribution 
by protecting NPs from opsonization (15). Despite the multiple 
advantages, functionalizion with PEG can induce complement 
activation (5, 35, 36). In addition, subsequent injections of 
PEGylated liposomes can result in their accelerated blood clear-
ance, probably due to transient IgM production (37). Another 
option for hydrophilic surface coating is polysaccharides. These 
naturally occurring molecules are a great alternative as they are 
characterized by low toxicity, low immunogenicity, biocompat-
ibility, stability, low cost, cryoprotection, and availability of 
reactive sites for chemical modification (38). A specific example 
is hyaluronan (HA), which is also characterized by bioadhesive 
properties as part of the extracellular matrix. In addition, HA is 
the major ligand for CD44 and CD168 receptors and, therefore, 
suitable for specific targeting to cells, such as those in tumors 
that overexpress these receptors (39–42).
Additional surface functionalization includes ligands that 
enable specific cell targeting, such as antibodies, peptides, and 
aptamers (15). However, despite the advantage, LNPs decorated 
with proteins or peptides can elicit an unwanted immune 
response, cross link receptors, and generate an outside-in signal-
ing cascade (43–45).
There are additional factors that induce immune activation of 
LNPs; among these are inhomogeneity of size or shape, multila-
mellar structure, endotoxin contamination, aggregation, and the 
presence of non-encapsulated drugs that can bind and aggregate 
lipids. Ultimately, it seems that the longest circulation time is 
obtained using LNPs that better mimic natural membranes. 
Therefore, there are increasing efforts to create LNPs using 
natural materials and even natural membrane-derived LNPs. 
Recently, Rodriguez et  al. have shown that surface modifica-
tion of LNPs with a “self ” peptide segment of CD47 resulted in 
reduced blood clearance by macrophages and, therefore, longer 
circulation time (46, 47).
The vast progress in the field of drug delivery enables tailor-
ing specific NPs for a particular location (TME, lymph nodes) 
and cell type while avoiding unwanted non-specific immune 
responses and toxicities as detailed below.
LNP-BAseD iMMUNOtHerAPies
immunomodulation of APcs
Therapeutic anticancer vaccination is a strategy that attempts to 
improve host immunity to cancer by upregulating host immune 
response against TAAs. Tumor vaccines deliver the antigen and/
or adjuvant to APCs for the activation of both humoral and cel-
lular immunity as presented in Figure 1.
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NP delivery can significantly boost immunogenicity of tumor 
antigens by co-delivery of antigens and adjuvants to the same 
location (48). One such platform is interbilayer-crosslinked 
multilamellar vesicles (ICMVs), which entrap high amounts of 
protein antigens in the vesicle core and lipid-based adjuvant in 
the vesicle walls (49). The authors found that ICMVs elicited 
robust antibody titers greater than simple liposomes or multi 
lamellar vesicles of identical lipid compositions. These synthetic 
vesicles triggered steadily increasing antibody production and 
CTL responses following repeated administrations.
Several NP-based vaccine formulations have been developed 
to deliver antigens specifically to APCs, especially to DCs and 
TAMs. Recently, Kranz et al. (50) used RNA-lipoplexes (RNA-
LPX), which are LNPs encapsulated with an RNA-encoded 
antigen, for systemic targeting of DCs. Targeting the DCs by 
RNA-LPX is based on optimally adjusting the net charge of the 
LNPs without functionalization of particles. RNA-LPX encoding 
antigens induce strong effector and memory T-cell responses 
and mediate potent IFNα-dependent rejection of progressive 
tumors. Leuschner et al. developed LNPs platform encapsulated 
with siRNA for modulation of monocytes and macrophages 
(51). The authors used this platform to encapsulate siRNA 
against CCR2, an important monocyte homing factor, and tested 
it in a mouse lymphoma model. Systemic administration of these 
nanoparticles resulted in a lower numbers of TAMs and reduc-
tion of tumor size.
Others have shown targeting of DCs using NPs decorated 
by specific anti DC antibodies. For example, Macho-Fernandez 
et al. (52) used NPs generated from poly lactic-co-glycolic acid 
(PLGA), coated with lipid-PEG and decorated by Abs recognizing 
DEC205, a cell-surface receptor that is expressed on spleen and 
lymph node CD8+ DCs. Using these NPs, they have demonstrated 
that co-delivery of an agonist (a-GalCer) and a protein antigen 
(ovalbumin) to CD8+ DCs triggers optimal humoral and CTL 
responses. In addition, this platform promotes potent antitumor 
responses in a B16F10 murine melanoma tumor model.
immunomodulation of tumor cells 
and tMe
Over time, cancer cells can develop phenotypes that are less 
immunogenic in order to escape immune surveillance. One strat-
egy used by cancer cells is an elevated expression of self-markers 
to avoid immune recognition by professional phagocytes. An 
example of using this strategy is the over expression of CD47 
on the cancer cell surface, which labels the cells with the “self ” 
marker and correlates with poor clinical prognosis (53–55). 
Yang et al. developed a systemic delivery strategy based on CD47 
siRNA encapsulated in HA-coated LNPs, which led to an efficient 
knockdown of CD47 in cancer cells. Decreased expression of 
CD47 eventually led to growth inhibition of melanoma tumors 
and suppressed lung metastasis in a B16F10 murine melanoma 
tumor model (56).
Additional strategy used by cancer cells to avoid immune 
recognition is secretion of anti-inflammatory cytokines. Anti-
inflammatory cytokines prevent the recruitment of immune cells 
to the TME and suppress the ability of resident immune cells to 
act against tumor cells. In order to block these complex interac-
tions, immune modulation based on targeting both the tumor 
cells and DCs was developed by Xu et al. (57). They delivered a 
combination of NPs: liposome–protamine–HA NPs encapsulated 
with siRNA against the immune-suppressive cytokine TGF-β, and 
mannose-modified lipid–calcium–phosphate NPs encapsulated 
with tumor antigen and adjuvant. TGF-β downregulation boosted 
the vaccine efficacy and inhibited tumor growth, as a result of 
increased levels of tumor infiltrating CD8+ T-lymphocytes and 
decreased level of Tregs.
A liposomal polymeric gel system developed by Park et  al., 
which combines the delivery of TGF-β inhibitor and the pro-
inflammatory cytokine IL-2, is another example for a complex 
approach of immunomodulation (Figure  2) (58). IL-2 was 
shown to enhance NK and CTL activity against several cancer 
types; however, this ability is hampered due to the secretion of 
anti-inflammatory agents, such as TGF-β by tumor cells (59). The 
authors showed a significant reduction of tumor growth in vivo 
and an increased immune response.
Another example of combining several immunotherapy 
strategies was recently presented by Moynihan et  al. (61). The 
authors used the amphiphilic vaccine platform containing a 
tumor antigen and adjuvant conjugated to albumin binding lipid. 
This enables utilizing the “albumin hitchhiking” strategy upon 
which binding with albumin directly targets molecules to lym-
phatics and draining LNs, thereby allowing them to accumulate 
in APCs. This platform was combined with systemic administra-
tion of tumor antigen-specific antibodies, IL-2, and anti- PD-1 
antibodies. The authors showed recruitment of both innate and 
adaptive immune cells that led to elimination of large established 
tumor burdens in syngeneic and genetically engineered murine 
tumor models. The treatment also elicited long protective T cell 
memory response.
seQUeNtiAL treAtMeNt OF 
cHeMOtHerAPY FOLLOWeD BY 
iMMUNOtHerAPY
A combined chemo-immunotherapeutic approach may be 
beneficial for the efficient elimination of cancer. Chemotherapy 
eliminates tumor cells, causing the cancer to shrink. As a result, 
tumor-derived antigens, such as peptides or proteins isolated 
from the tumor cells, can be efficiently internalized by APCs, 
thereby increasing the antitumor immunity of CTL. Lu et al. (62) 
developed cisplatin LNPs and CpG-encapsulated liposomes for 
treatment of melanoma. Such combination therapy established 
strong synergistic effects, both on the apoptotic level and subse-
quent abrogation of tumor growth. Heo et al. (63) sequentially 
subjected tumor-bearing mice to chemotherapy consisting of 
pacitaxel dissolved in HA in addition to immunotherapy using 
CpG ODNs and IL-10 siRNA incorporated into PLGA NPs. The 
sequential treatment with chemotherapeutic drugs followed by a 
combined immunostimulation strategy resulted in a synergistic 
effect against solid tumors.
A recent study by He et  al. designed coordination 
polymer LNPs, which combines two therapeutic modalities, 
FigUre 2 | Lipid nanoparticle (LNP)-based cytokine remodeling of tumor microenvironment (tMe). The TME manages to escape immune surveillance via 
production of immunosuppressive cytokines, such as TGF-β and IL-10. TGF-β inhibits both innate and adaptive immune responses by suppressing the activity of 
CD8+T-lymphocytes (CTL) and natural killer (NK) cells as well as triggering the expansion of Tregs. LNPs entrapping both TGF-β inhibitor and IL-2 manage to reverse 
this effect by directly activating both NK and CTL, while also depleting Tregs; thus restoring both adaptive and innate antitumor responses [modified from Ref. (60)]. 
Reproduced by permission from Macmillan Publishers Ltd: Nature Materials, 11, 831–832 (2012), copyright 2012.
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chemotherapy and photodynamic therapy, to elicit antitumor 
immunity (64). These LNPs kill cancer cells by inducing 
apoptosis and necrosis, stimulating host immune system, and 
causing an acute inflammation and leukocyte infiltration to the 
tumors; all of which increase the presentation of tumor-derived 
antigens to T cells. Combining polymer NPs treatment with 
PD-L1 checkpoint blockade therapy led to the regression of 
the primary tumors treated locally with irradiation, and also 
resulted in the regression of the distant tumors in bilateral 
syngeneic mouse tumor models of CT26 and MC38.
cONcLUsiON AND FUtUre OUtLOOK
Cancer immunotherapy has been getting a lot of attention in the 
past few years and for many good reasons. There are multiple 
benefits for immunotherapy in comparison to conventional 
medicine, as the former treatment modality enables utilization 
of the immune system to eliminate tumor cells, while leaving 
healthy cells untouched. As our understanding of the complex 
interplay between cancer cells and the immune system deep-
ens, the potential for achieving efficient therapeutics grows. 
Advances in research in the past few years have provided a 
solid basis for the development of several therapeutic strategies 
on the basis of targeting specific pathways and checkpoints. 
Further understanding of the immunosuppressive TME and 
antitumor immunity is the key for successful treatments 
and avoiding unfavorable outcome such as induction of 
autoimmunity.
NP-based immunotherapy provides multiple advantages 
upon administration of immune modulators since it enables 
targeted delivery both locally and temporally, therefore 
enhancing the effectiveness and reducing toxicity. It also 
enables transport of several compounds simultaneously and 
delivery of RNAi-based therapeutics, significantly increasing 
the therapeutic index.
A successful immunotherapy requires both innate and adop-
tive responses. Tumor cells utilize several mechanisms to escape 
immune recognition and induce immune-suppressive TME; 
thus, tackling only one pillar would not be sufficient. This may 
be responsible for the limited clinical achievements of current 
immunotherapy. Indeed, recent treatments combining several 
immune effectors were reported to be synergistic. The identifica-
tion of the optimal combination of NPs and immune modulators 
for the appropriate TME is also crucial, and further development 
may be aided by the use of computerized biology. Improvement 
of currently used murine tumor models to appropriately reflect 
the complex TME is also required. Many reports are treating 
early-stage tumors in which the immune-suppressive TME is 
not completely developed. In addition, direct manipulation of 
tumor-residing lymphocytes has not yet been achieved and 
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the appropriate delivery system is still an unmet need. This 
is especially significant in light of the recently approved anti 
T-lymphocyte treatments (anti-CTLA-4 and anti-PD-1 antibod-
ies) that emphasize the potential of T-lymphocyte modulation 
for immunotherapy. Currently, lymphocyte manipulation can be 
achieved indirectly via specific modulators; and direct targeting 
of specific subsets of APCs has already been demonstrated. Some 
reports even show this simply by controlling lipid composition 
or charge, avoiding the use of targeting moieties altogether. The 
effectiveness of such untargeted systems in humans still has yet to 
be determined. To date, impressive therapeutic effects have been 
achieved upon using adoptive cell transfer therapy; however, 
this approach is not feasible for large-scale treatment. Therefore, 
the optimal NP-based system should include the appropriate 
immune mediator combination that would elicit highly effective 
and wholly endogenous response.
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